Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for secondary prophylaxis of thrombocytopenia in newly diagnosed glioblastoma
2012-001751-38Phase 2Terminated
- Sponsor
- CHU de Lille
- Start
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of romiplostim in glioblastoma (GBM) and chemotherapy-induced thrombocytopenia (CIT), sponsored by CHU de Lille. Primary endpoint: Proportion of patients receiving 100% of planned temozolomide dose in Stupp protocol. Started Dec 2013; status: terminated.
02
Drugs
romiplostim
03
Conditions
glioblastoma (GBM)chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on 2012-001751-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001751-38.